ADC TOXICITY ATLAS
AtlasPayloads and LinkersPayloadsTargetsMethods
← Atlas

Farletuzumab (naked Ab)

Discontinued
MORAb-003
Sponsor
Morphotek/Eisai
Indication
FOLR1+ ovarian
Target family
GPI-anchored
RP2D dose
2.5 mg/kg
Q1WRP2D
01
Multi-organ toxicity

Fingerprint & organ drill-down

Also reported
0%severity100%
0
Assessed · clear
true 0%
No data
never assessed
3 adverse-event terms

Ocular

Any-grade
0%
G3+
0%
RP2D
sagittal schematic · Unknown
↳

Tissues shaded by reported adverse-event rate.

Cornea
AE
-
Express.
0.02%
Limbus
AE
-
Express.
0.07%
Conjunctiva
AE
-
Express.
0.19%
Lens
AE
-
Express.
-
Retina / RPE
AE
-
Express.
3.21%
0.4 nTPM
Dominant tissue
-
Surface subtype
None
Reversibility
Unknown
Reported ocular events
Lacrimation increased5.3%
Ocular adverse event (keratopathy / dry eye / blurred vision)0%
n=367
Retinal detachment (serious)-
G3+ 0%
02
Construct

Molecular anatomy

Antibody
IgG1
Humanized
Linker
DAR
Payload
N/A (naked antibody)
Linker structure
structure not applicable
Payload structure
structure not applicable
03
Antibody

Antibody & Fc engineering

Antibody
farletuzumab
Isotype
IgG1
Origin
Humanized
Fc modifications
None
Glycoengineering
Standard
Effector silencing
None
FcγR binding
Retained
C1q binding
Retained
04
Linker & conjugation

Linker chemistry

Linker profile
Linker
N/A (naked antibody)
Class
-
Cleavage
-
Attachment
-
Conjugation
Not applicable (naked antibody)
Symmetry
N/A
DAR (mean)
-
DAR homogeneity
N/A
Plasma t½
-
Cleavage trigger
N/A
Release control
N/A
Hydrophilicity mask
N/A
Formula
-
Linker MW
-
Linker TPSA
-
Linker xLogP
-
ADCdb linker
-
In-vitro stability
N/A
Stability note
Naked anti-FOLR1 antibody — no payload, no linker. Plasma t½ governed by neonatal Fc receptor recycling typical of IgG1 (~21 d) but t½ axis is not toxicity-relevant for this molecule because there is no warhead
05
Payload

Payload & physicochemistry

Payload profile
Payload
N/A (naked antibody)
Class
-
Mechanism
-
Released catabolite
N/A
Mechanistic subtype
N/A
Stereochem / salt
N/A
Bystander
-
PAMPA rank
-
MW
-
XLogP3
-
logD₇.₄
-
TPSA
-
pKa
-
Charge pH 7.4
-
H-bond donors
-
H-bond acceptors
-
IC50 (HCEC)
-
Formula
-
PubChem CID
-
ADCdb payload
-
Bioactivity note
Mechanism is payload-independent: farletuzumab is a naked anti-FRalpha mAb acting via ADCC, CDC, induction of autophagy, and inhibition of FRalpha-Lyn kinase growth signaling; it does not block folate binding/transport. No cytotoxic-payload IC50 applies.
06
Dosing & regimen

Dosing

RP2D dose
2.5 mg/kg
Schedule
Q1W
Route
IV
Fractionated
No
n at RP2D
1100
Dose basis
TBW
Trial phase
Phase 3
Dose-OAE available
No
Tox summary basis
RP2D
07
Ocular & expression

Ocular profile & eye-tissue target expression

Target profile
OAE any-grade
0 %
OAE grade 3+
0 %
OAE data status
documented-absent
Severity (weighted)
0
Keratopathy
-
Conjunctival
-
Dry eye
-
Blurred vision
-
Dominant tissue
-
Surface subtype
None
Grading scale
Unknown
Reversibility
Unknown
Target expression in eye tissues (HCA detection · HPA bulk)
Cornea (central)
0.02 %
Cornea (limbal)
0.07 %
Conjunctiva
0.19 %
RPE
3.21 %
Retina (HPA)
0.4 nTPM
Cross-trial comparability
Ascertainment: Symptom-driven reportingScale: UnknownDenominator: RP2D⚠ OAE rate not directly comparable across trials
08
Identity & registry

Identifiers, registry & notes

ADC id
farletuzumab
Approval status
Discontinued
Approval year
-
UniProt
P15328
ADCdb ADC
-
ADCdb antibody
ANI0TZBRZ
ADCdb target
TAR0QHAVI
Primary source
Vergote JCO 2016;34(19):2271 (PMID 27001568)
Aliases & development codes
MORAb-003
Notes
Naked antibody — 0% OAE confirms OAE signal is entirely payload-driven. V3.1: n=1100 is Vergote 2016 total Phase 3 enrollment across 3 farletuzumab arms; 2.5 mg/kg arm ~367.